Meeting
2018 ASCO Annual Meeting
Neoadjuvant androgen deprivation therapy and enzalutamide: Imaging and pathological responses.
Authors
David James VanderWeele
University of Chicago Medical Center, Chicago, IL
David James VanderWeele , Baris Turkbey , Fatima Karzai , Stephanie Harmon , Adam G. Sowalsky , Huihui Ye , Scott Wilkinson , Guinevere Chun , Samuel A Gold , Peter A. Pinto , Peter L. Choyke , William L. Dahut
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Genitourinary (Prostate) Cancer
Track
Genitourinary Cancer—Prostate, Testicular, and Penile
Sub Track
Prostate Cancer–Local-Regional Disease
Clinical Trial Registration Number
NCT02430480
Citation
J Clin Oncol 36, 2018 (suppl; abstr 5082)
DOI
10.1200/JCO.2018.36.15_suppl.5082
Abstract #
5082
Poster Bd #
309
Abstract Disclosures
Similar Posters
Poster
2019 Genitourinary Cancers Symposium
A study of intense neoadjuvant testosterone lowering therapy with goserelin and enzalutamide (Enza) in high-risk prostate cancer (PC) with multiparametric MRI (mpMRI).
First Author: Fatima Karzai
Poster
2022 ASCO Annual Meeting
Randomized phase II trial of neoadjuvant androgen deprivation therapy plus abiraterone and apalutamide for patients with high-risk localized prostate cancer: Pathologic response and PSMA imaging correlates.
First Author: Diogo Assed Bastos
Poster
2020 Genitourinary Cancers Symposium
Multiple primary prostate tumors with differential drug sensitivity.
First Author: Scott C. Wilkinson
Poster
2019 ASCO Annual Meeting
Targeting backdoor androgen synthesis through AKR1C3 inhibition: A presurgical hormonal ablative trial in high risk localized prostate cancer (PC).
First Author: Laura Graham